Ubrolexin

Contraindications
Do not use in lactating dairy cows with a known hypersensitivity to cefalexin and/or kanamycin. Do not use in non-lactating cattle.
Do not use where resistance is known to occur.

Adverse reactions
None known

Withdrawal periods
Meat and offal: 10 days
Milk: 5 days

Special precautions for use in animals: Recommendations for prudent use
The product should be used for treatment of clinical mastitis, only.
Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional and farm level) epidemiological information about susceptibility of the target bacteria as well as by taking into account official national antimicrobial policies.
Inappropriate use of the product may increase the prevalence of bacteria resistant to cefalexin and kanamycin and may decrease the effectiveness of treatment with other cephalosporins or aminoglycosides due to the potential for cross-resistance.

Use during pregnancy and lactation:
The product can be used in pregnant cows.
The product is intended for use during lactation.

Interaction with other medicinal products and other forms of interaction
In case of resistance to cefalexin, cross-resistance with other cephalosporins is likely to occur. In case of resistance to kanamycin, cross-resistance occurs between kanamycin, neomycin and paromomycin. A one way resistance with streptomycin is known.

Manufacturer:
Univet Ltd., Ireland.

Marketing Authorization Holder:
Boehringer Ingelheim, Germany.